Artificial Intelligence
Clarivate Identifies Seven Potential Blockbuster Drugs in Annual Drugs to Watch Report
Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch™ report, identifying drugs entering the market or launching key indications in 2022 which are predicted to achieve blockbuster status by 2026. Leveraging Clarivate data and insights, analysts identified seven late-stage experimental treatments that they forecast will deliver annual sales of more than $1 billion within five years. These treatments span a remarkably diverse set of therapeutic areas, from conditions like Alzheimer’s disease (AD), asthma and type 2 diabetes mellitus (T2DM), which afflict tens of millions of patients worldwide, to rare diseases, such as transthyretin amyloidosis (ATTR), among others.
The report also offers an in-depth analysis of key COVID-19 vaccines and therapies along with key therapeutic development areas to watch, such as cell and gene therapies, CRISPR, drug discovery driven by artificial intelligence and machine learning, RNA and targeted cancer therapies. In addition, the report examines blockbuster drugs and biologics facing generic competition due to U.S. patent expirys in 2022.
Navigating the global healthcare landscape is increasingly complex, and discovering, developing and commercializing successful treatments that change patient lives can be challenging, especially during today’s unprecedented times. The Drugs to Watch report highlights experimental treatments with great promise to realize improved patient outcomes and efforts to finance the next generation of innovative medicines. Through adaptation, improvisation and crowdsourcing solutions, the companies behind these promising treatments are advancing a broad array of innovative treatment candidates – leveraging deep expertise in their relevant therapeutic areas and long-term strategies for pursuing therapeutic solutions for these conditions.
Among new drugs and biologics that have either won approval or are poised to do, Clarivate has identified seven treatments that it believes are likely to achieve blockbuster status in the next five years. The 2022 Drugs to Watch, include:
- Adagrasib, developed by Mirati Therapeutics Inc and Zai Lab Limited – This long-awaited, targeted treatment will likely be the first such treatment option in patients with colorectal cancer (CRC) with the KRASG12C mutation, who historically have had very few treatment options. The common variants of the KRAS oncoprotein are traditionally considered intractable drug targets which makes the forecasted entry of a KRAS inhibitor for patients with mutation-positive solid tumors so monumental.
- Faricimab, developed by Roche and Chugai Pharmaceutical – For patients with diabetic macular edema (DME) or wet age-related macular degeneration (AMD), faricimab offers a potentially more convenient option as it will be administered less frequently, on average, than the standard of care. As the first bispecific antibody to launch in ophthalmology, it also has the potential to be more efficacious than current standard of care, although data so far indicates it is non-inferior to the standard of care. Faricimab is the first dual VEGF/Ang-2 inhibitor to treat DME and wet AMD (and the first bispecific MAb in the ophthalmology therapeutic area overall).
- Lecanemab, developed by Eisai Co Ltd and Biogen Inc, and donanemab, from Eli Lilly and Company – In this underserved market, anti-Aβ MAbs lecanemab and donanemab are poised to follow on the heels of the U.S. FDA’s landmark accelerated approval of ADUHELM for the treatment of AD. Lecanemab and donanemab could offer differentiated clinical profiles, which may be bolstered by phase 3 results that are expected to be reported beginning in late 2022. Data across clinical trials suggest that sufficient exposure to optimal doses of anti-Aβ MAb therapy could be clinically effective in early AD.
- Tezepelumab, developed by Amgen and AstraZeneca – Tezepelumab is a potential game changer for patients with non-TH2 or TH2-low asthma whose asthma is not well-controlled with inhaled corticosteroids, the current standard of care. If approved, it would be a first-in-class biologic for this patient population. Tezepelumab will likely be a first-line biologic for severe TH2-low asthma and a treatment option for patients with TH2-high asthma for whom existing therapies have been less successful.
- Tirzepatide, developed by Eli Lilly and Company – Tirzepatide offers indication-leading reductions in weight loss and improvements in glycemic control in a growing patient population, which has the potential to reduce the incidence of type 2 diabetes mellitus (T2DM)-related complications. A new treatment that can more effectively address both weight loss and glycemic control than existing treatments would potentially be of great benefit to patient outcomes.
- Vutrisiran, developed by Alnylam Pharmaceuticals – For a progressive disease with a lot of unmet need, this drug brings efficacy, a generally favorable safety profile, and improvements in delivery that will benefit patient quality of life. This patient population has few treatment options, especially for those with wild-type ATTR. Not only does this drug enter a relatively underserved market overall, it also has more convenient dosing than other ATTR-specific drugs on the market.
Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership, Clarivate: “While pharmaceutical and biotech companies have invested substantial intellectual capital in the past two years tackling the challenges wrought by COVID-19, they have also continued to harness new technologies to create medicines that will provide options for patients with poorly or currently untreatable diseases that still represent a significant medical burden. This year’s drugs-to-watch picks, as well as the technologies-to-watch selections, highlight the robust innovation that is at the heart of the pharma and biotech sector and will underpin better outcomes for patients in the future.”
Despite the COVID pandemic having disrupted the drug industry in many ways, from supply chain collapse-induced shortages of key components1 to clinical trial delays2, pharma and biotech companies continue to drive major advances in medicine. Drugmakers are making great strides towards unlocking technologies that will facilitate personalized medicines. Regulators are showing an openness to new technologies and methodologies and an eagerness to address diseases for which there are few or no treatments. However, it remains critical for companies to prove their value to win market approval and make them accessible to patients.
Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerating innovation, Clarivate’s end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions.
The full Drugs to Watch Report is freely available online here.
For more Drugs to Watch updates and analyses throughout the year, visit the Drugs to Watch web page and follow Clarivate for Life Sciences & Healthcare Twitter and LinkedIn. #DrugstoWatch2022
Methodology for the Clarivate Drugs to Watch 2022 Report
To identify this year’s Drugs to Watch, we drew from the expertise of over 160 analysts covering hundreds of diseases, drugs and markets and eleven integrated data sets that span the R&D and commercialization lifecycle, including: Cortellis Competitive Intelligence™, Disease Landscape & Forecast, BioWorld™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Generics Intelligence™, Cortellis Deals Intelligence™, Access & Reimbursement payer studies, Clarivate Real World Data and Analytics, Web of ScienceTM, Derwent Innovation™ and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2021 were selected for analysis, including drugs launched for a new indication that could be particularly impactful on the industry; drugs launched prior to 2021 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2026. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors. Please note that Clarivate analysts generated the data shown in this report prior to December 24, 2021.The Drugs to Watch 2021 Report and the treatments referenced in this release are based on Clarivate’s current expectations based on existing data, but actual results derived from the drugs identified in the Report and herein may differ significantly.
To learn more about how the evolving R&D landscape creates many new opportunities and challenges to the traditional blockbuster model, join Michael Ward and Kenneth Beers of Clarivate on January 20, 2022 for a presentation on “R&D in an Age of Multiplying Modalities and Targets,” during 2022 Fierce JPM Week. Visit https://www.fiercejpmweek.com/ for more information.
To learn more about Clarivate data products, visit www.clarivate.com.
Artificial Intelligence
Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects
MORRISVILLE, N.C., May 28, 2024 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the availability of spectral data files as an option for Global Discovery Panel projects, providing clients with an enhanced level of detail and transparency in metabolomics analysis. The addition of spectral data further complements Metabolon’s robust suite of metabolomics offerings, including the largest Level 1 library of metabolites, an advanced bioinformatics platform, and expert scientific support.
Spectral data is the initial data generated during a mass spectrometry (MS)- based metabolomic analysis. Spectral data contains a wealth of information about the metabolites present in a sample, including their chemical structure, concentration, and interactions with other molecules. Metabolon facilitates further exploration of the dark metabolome and validation of findings by offering spectral data files as an option with Global Discovery Panel projects. These data should enable the discovery of unique metabolites and biomarkers.
“The availability of spectral data enhancement not only provides clients with a more comprehensive view of their metabolomics data but also reinforces our commitment to transparency and delivering unparalleled value to our clients,” said Ro Hastie, CEO at Metabolon.
This significant update underscores Metabolon’s commitment to providing comprehensive and actionable insights to empower scientific discoveries and drive advancements in healthcare and multiomics research. Visit https://www.metabolon.com/ to learn more about how Metabolon deciphers thousands of discrete chemical signals to discover biomarkers and reveal biological pathways.
About Metabolon Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is enabled by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
About MetabolomicsMetabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Logo – https://mma.prnewswire.com/media/1671125/Metabolon_Inc_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/metabolon-now-includes-spectral-data-files-for-all-global-discovery-panel-projects-302156728.html
Artificial Intelligence
Caseware Introduces AiDA: The AI-Powered Digital Assistant Changing the Face of Accounting and Audit
TORONTO, May 28, 2024 /PRNewswire/ — Caseware International, a global leader in cloud-enabled audit, financial reporting and data analytics solutions, is delighted to announce the pre-launch availability of Caseware AiDA, its Artificial Intelligence digital assistant. As the latest enhancement to the industry-leading Caseware Cloud platform, AiDA complements Caseware’s comprehensive suite of solutions created with accounting, audit and finance professionals in mind.
AiDA is designed to enhance efficiency, ensure compliance and provide precise, context-aware responses to profession-specific enquiries enabling accounting, audit and finance experts to work more efficiently, collaborate with greater effectiveness and gain deeper insights.
Whether providing timely responses to methodology or compliance questions, supporting the processing and analysis of audit evidence, or assisting with the production of key audit workpapers and deliverables, AiDA empowers professional users to achieve more with less effort. This will, in turn, drive practice growth and power the financial success of clients.
David Osborne, Chief Executive Officer at Caseware International remarked, “Caseware AiDA is the future. Our vision is to place powerful tools in the hands of our clients, enabling them to do their work better than they have ever done before. This release is just the beginning of a wave of innovation in AI and it demonstrates the focus we have on our accelerated roadmap to build out our offering on the Caseware Cloud platform. Caseware AiDA offers powerful digital assistance to accountants and is further proof of the ways in which Caseware is underpinning the relevance of the profession.”
Some of the benefits to be gained from Caseware AiDA include:
Enhanced workflow efficiency with precision and relevance – whether summarizing lengthy PDFs or providing informed answers about your documentation in the moment, AiDA helps you work smarter, not harder.Reassurance around security and compliance – with AiDA, no prompts are stored or fed back into the model. Users can trust AiDA to maintain the highest data security and compliance standards that Caseware has always delivered for the profession.Assistance with routine tasks – AiDA assists with mundane tasks, enabling professionals to focus on strategic decision-making.Focus on quality output – AiDA delivers a safe and fit-for-purpose resource which ensures efficient workflows for clients.Feedback on AiDA has underscored the demand for tailored, secure AI solutions in professional environments. Danielle Supkis Cheek, VP, Head of Analytics and AI at Caseware International commented, “We recently showcased AiDA to a number of clients beyond our beta phase community at Caseware’s 2024 North American User Group. The response was phenomenal and, in line with our roadmap, we’re excited to continue to enhance AiDA based on user feedback and technological advancements.”
Currently available to Caseware Cloud customers in the United States for early access, AiDA will ultimately be available across the globe and, specifically, in Australia, Canada and Europe later this year. Soon, AiDA will be a core component of all cloud-enabled solutions, across all regions. AiDA’s capabilities are constantly evolving, including better context awareness in document interactions and more extensive support for multilingual queries. AiDA is set to transform how professionals in the accounting and audit fields manage their tasks, offering unparalleled support and efficiency.
Caseware AiDA (pronounced AY-duh) draws inspiration from Ada Lovelace, whose impact on scientific computing continues to influence generations of technologists and mathematicians around the world.
Caseware encourages users to explore AiDA’s features and experience the future of digital assistance. To see AiDA in action, join us at ENGAGE at the ARIA Resort & Casino from June 3-6 or sign up to hear more from Danielle Supkis Cheek at the Streamlining Audits with AI: Efficiency and Quality Gains webinar taking place at 11:00 AM ET on July, 18.
About Caseware InternationalCaseware is the leading global provider of desktop and cloud-enabled solutions for audit, assurance, financial reporting and data analytics for accounting firms, corporations, and government regulators. Caseware’s innovative tools and platforms help more than half a million customers in 130 countries work smarter, dig deeper and see further as they transform insights into impact. For more information, visit www.caseware.com.
Notes to editorsIn the event of media enquiries, please contact:Jill QuinnDirector of Corporate CommunicationsCaseware [email protected]
Photo – https://mma.prnewswire.com/media/2421134/CaseWare_International_Inc__Caseware_Introduces_AiDA__The_AI_Pow.jpg
Photo – https://mma.prnewswire.com/media/2421135/CaseWare_International_Inc__Caseware_Introduces_AiDA__The_AI_Pow.jpg
View original content:https://www.prnewswire.co.uk/news-releases/caseware-introduces-aida-the-ai-powered-digital-assistant-changing-the-face-of-accounting-and-audit-302155473.html
Artificial Intelligence
LONGi announces the “Lighthouse Project” to expand the agile intelligent manufacturing to more of its own production bases across the globe
JIAXING, China, May 28, 2024 /PRNewswire/ — On May 23rd, LONGi Green Energy Technology Co., Ltd. (hereinafter referred to as “LONGi “), a global leader in solar technology, officially announced the “Lighthouse Project”, which will continue to rapidly expand the agile intelligent manufacturing model of LONGi’s Jiaxing Lighthouse Factory to more production and manufacturing bases, achieving a comprehensive upgrade of production intelligent manufacturing capabilities. This sets a digitalization benchmark for high-quality development in the PV industry and leads the way forward.
The first “Lighthouse Factory” in the global PV industry – LONGi’s Jiaxing Production Base, lifted the mysterious veil for the public. An experience group composed of industry experts, customer representatives, and media journalists became the first visitors to LONGi’s Jiaxing Lighthouse Factory, immersing themselves in the production line and experiencing the charm of “Lighthouse Factory” intelligent manufacturing.
Established in 2020, LONGi’s Jiaxing Production Base mainly produces LONGi’s BC (Back-Contact) series of high-efficiency solar modules. It has Phase I, II, and III factories, covering a total area of more than 1,300 acres, with 51 intelligent production lines and an overall module production capacity exceeding 35GW, making it one of the largest industrial clusters in the industry.
On December 14, 2023, the World Economic Forum (WEF) released a new batch of “Lighthouse Network” lists, and LONGi’s Jiaxing Production Base was the only factory in the global PV industry to be included. This signifies that LONGi’s achievements in intelligent manufacturing and digitalization are leading globally, becoming a representative of advanced manufacturing, and the first global “Lighthouse Factory” in the PV industry has attracted much attention.
During this close-up experience at LONGi’s Jiaxing Lighthouse Factory, all members of the experience group expressed their shock and unprecedentedly felt the disruptive upgrade of AI intelligence to traditional industry. The innovation of LONGi’s Jiaxing Lighthouse Factory is not only in the transformation of production line automation and intelligence but also in the reconstruction of production relations. AI intelligence has become the brain of production management, continuously innovating autonomously based on big data models, achieving a truly meaningful intelligent manufacturing upgrade and self-driving force, and safeguarding quality and efficiency.
LONGi’s Jiaxing Lighthouse Factory has built over 30 digital use cases, achieving a 43% increase in product quality reliability, an 84% reduction in product production and delivery cycle, and a 20% reduction in overall unit energy consumption at the base, becoming a model of high-quality development in the photovoltaic industry.
The most core aspect of LONGi’s Jiaxing Lighthouse Factory is the five major coolest technologies. AI intelligent distribution of solar cells realizes precise delivery of customer needs, ensuring efficient production by intelligently optimizing daily production plans. More flexible automation in production ensures the standardization of each link in the module production process, fully meeting the customized scene requirements of customers. AI quality inspection throughout the entire life cycle of product production leaves no place for quality hazards, ensuring the quality of the product is as solid as a rock. The end-to-end delivery system has reconstructed the intelligent management of order production and delivery cycles, achieving rapid and high-quality satisfaction of customer product needs. Intelligent human resource management has greatly improved production efficiency while enhancing the innovation of employees, transforming each excellent skill and experience into data, continuously optimizing skills and management autonomously, ensuring the optimal arrangement of order demands and human resources, and effectively guaranteeing high-quality product output.
The combination of artificial intelligence, big data, cloud platforms, and industrial muscles is the four elements that make LONGi’s Jiaxing Lighthouse Factory successful, and also the core of LONGi’s intelligent manufacturing. LONGi’s BC (Back-Contact) full-scene products have also reached a new level under the support of LONGi’s intelligent manufacturing. The reason why TaiRay silicon wafers, HPBC2.0, Hi-MO 9, Hi-MO X6 Max, and other major products have concentrated on explosions this year is due to LONGi’s intelligent manufacturing’s absolute satisfaction in understanding customer needs.
LONGi’s Vice President Zhang Haimeng said in his keynote speech: Since the official announcement of BC (Back-Contact) technology last September, LONGi has released multiple new scene-based module products. Whether it is anti-dust accumulation or heat and humidity resistance, the core purpose is to meet the customized needs of customers through differentiated innovation. All of this is inseparable from the confidence in production strength brought by LONGi’s intelligent manufacturing, and it is also the strong support of LONGi’s intelligent manufacturing that has truly implemented “customer-centric.”
During the panel session of the day, Hu Zhifeng, Head of Intelligent Manufacturing Department, Module Manufacturing Center of LONGi, revealed that the newly launched Hi-MO X6 Max modules will be officially put into production at LONGi’s Jiaxing Lighthouse Factory in the near future. With the help of digital and intelligent means, product quality is improved, and energy consumption is reduced. “Use the most advanced production technology to achieve the highest level of technical products and create higher value for customers.”
LONGi has always adhered to the core value of customer value, providing customers with high-value and reliable products as its own responsibility, continuously exploring new paths for the clean energy industry, from efficiency research and development to product and solution scenario, from traditional manufacturing to intelligent manufacturing driven by digitalization, step by step towards a green energy world, leading the global energy transition with LONGi’s intelligent manufacturing.
About LONGi
Founded in 2000, LONGi is committed to being the world’s leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation.
Under its mission of ‘making the best of solar energy to build a green world’, LONGi has dedicated itself to technology innovation and established five business sectors, covering mono silicon wafers cells and modules, commercial & industrial distributed solar solutions, green energy solutions and hydrogen equipment. The company has honed its capabilities to provide green energy and has more recently, also embraced green hydrogen products and solutions to support global zero carbon development. www.longi.com
Photo – https://mma.prnewswire.com/media/2422491/LONGi_announces__Lighthouse_Project__expand_agile_intelligent_manufacturing_production_bases.jpgPhoto – https://mma.prnewswire.com/media/2422492/LONGi_announces__Lighthouse_Project__expand_agile_intelligent_manufacturing_production_bases.jpgLogo – https://mma.prnewswire.com/media/1606520/LONGi_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/longi-announces-the-lighthouse-project-to-expand-the-agile-intelligent-manufacturing-to-more-of-its-own-production-bases-across-the-globe-302156707.html
-
Artificial Intelligence4 days agoTitans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Uncategorized4 days agoGienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence4 days agoBybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Artificial Intelligence6 days agoHONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence4 days agoOverseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence4 days agoIoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence4 days agoNorthern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
